Aligos Therapeutics' P/S ratio remains below industry median...

Aligos Therapeutics' P/S ratio remains below industry median due to poor revenue outlook. Without significant change, a drastic stock price rise is unlikely. The low P/S ratio is justified by inferior revenue forecasts.